NEW YORK, Oct. 26, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Renal Associates Holdings, Inc. securities (NYSE:ARA): (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016 of the important October 31, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for American Renal investors under the federal securities laws.
To join the American Renal class action, go to the firm’s website at http://www.rosenlegal.com/cases-946.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 31, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-946.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 



